SINTX Technologies Inc

SINTX Technologies Inc (SINT) Stock Analysis

$1.560

-0.058 (-3.70%)At close

Loading chart…
High
1.640
Open
1.640
VWAP
1.58
Volume
41.03K
Mkt Cap
3.17M
Low
1.550
Amount
64.96K
EV/EBITDA, TTM
-0.31

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah.

sintx.com

AI analysis of SINTX Technologies Inc (SINT)

Sell

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

Valuation Metrics

The current forward P/E ratio for SINTX Technologies Inc (SINT) is 0.00, compared to its 5-year average forward P/E of -19.40.

Forward P/E

Fair
5Y Average P/E
-19.40
Current P/E
0.00
Overvalued
59.35
Undervalued
-98.14

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-0.32
Current EV/EBITDA
-0.31
Overvalued
0.29
Undervalued
-0.94

Forward P/S

Fair
5Y Average P/S
4.14
Current P/S
2.03
Overvalued
8.10
Undervalued
0.19

Alphio AI Price Scenarios for SINT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%SINT

$2.63

Scenario price

B

Base

Base · 50%SINT

$1.91

Scenario price

B

Bear

Bear · 25%SINT

$1.46

Scenario price

Events Timeline

2026-11-05 (ET)

17:30:00

SINTX Technologies Reports Q3 Revenue of $2.19M

2026-10-01 (ET)

09:30:00

Sintx Technologies Reports $2.2M Revenue for Q3

2026-08-13 (ET)

06:30:00

Selling Stockholders Plan to Sell 1.27M Shares of Common Stock

2026-06-25 (ET)

06:30:00

Sintx Technologies Files to Sell 5.82M Shares of Common Stock

2026-06-22 (ET)

10:00:00

Sintx Technologies Secures Over $3.2M in Orders

News

SINT FAQ — answered by Alphio AI

SINTX Technologies, Inc. is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and agribiotech applications. It is engaged in the research, development, and manufacturing of silicon nitride. Its core business includes biomedical applications and antipathogenic applications. It has been focused on medical grade silicon nitride. Spinal implants made from its silicon nitride have been implanted in humans. This established use, along with its inherent resistance to bacterial adhesion and bone affinity suggests that it may also be suitable in other fusion device applications such as arthroplasty implants, foot wedges, and dental implants. Its composition of silicon nitride antipathogenic powder may enable manufacturing surfaces that inactivate pathogens, thereby limiting the spread of infection and disease. It manufactures advanced ceramic powders and components in its manufacturing facilities based in Salt Lake City, Utah. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

SINTX Technologies Inc is not a good buy right now due to its very low RSI of 23.718, indicating oversold conditions, and a significant year-to-date decline of 58.73%. The stock is currently trading at $1.56, which is only 5.2% above its 52-week low of $1.40, suggesting limited upside potential. Additionally, the company has reported substantial net losses, with a net income of -$3,632,000 in Q2 2026, raising concerns about its financial stability. The main risk is its high debt-to-equity ratio of 11.73% in Q1 2026, indicating potential liquidity issues.

Community

More ↗

No posts yet

Sign up or log in to join the discussion

Related articles

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Start trading